Building What Matters: Medicine Fabrication and the Critical Role of Modern Construction

As healthcare moves toward more personalized therapies, the facilities required to manufacture them are changing in fundamental ways.

ARTICLE SOURCE: Tim Vickers, Vice President – Project Development

Atlanta, GA – September 16, 2026 — For decades, pharmaceutical manufacturing was built around a relatively simple premise: produce millions of identical doses and distribute them around the world. Success was measured by scale, but that model is rapidly evolving.

Today’s breakthroughs are increasingly centered on the individual patient, and personalized medicines are changing the environments required to manufacture them. As production shifts away from large-scale, standardized outputs and toward specialized therapies, facilities must be designed as active participants in the manufacturing process. No longer passive containers for production, they are purpose-built environments that help protect the integrity of therapies from development through delivery.

The Shift From “One-Size-Fits-All” to Precision Medicine Fabrication

Tomorrow’s treatments won’t necessarily be made in million-dose batches. Instead, they may be tailored to the unique characteristics of an individual patient. Rather than being designed for broad populations, therapies are increasingly being developed around specific biological markers, disease characteristics and treatment responses.

A child receiving gene therapy, a cancer patient with a customized cell treatment, and a diabetic person using an AI-enabled insulin delivery system may all receive therapies specifically optimized for them.

These treatments blur the line between medicine, biotechnology, software, and engineering, creating new demands for the environments in which they are developed and manufactured.

As therapies become more specialized, manufacturing environments must support a level of flexibility, traceability, and quality control that traditional pharmaceutical facilities were never designed to provide. Facilities are being asked to manage smaller production runs, stricter handling requirements, increasingly complex regulatory expectations, and specialized cold chain logistics.

The challenge is not simply building faster; it is designing and constructing facilities capable of evolving alongside the products they support without requiring complete redevelopment.

When the Patient Is the Supply Chain

Perhaps the most profound shift is that, in some therapies, the patient’s own cells become the starting material.

For facility owners and builders, the implications are significant. Supporting autologous cell therapies requires environments designed around strict chain-of-custody controls, specialized cryogenic infrastructure, contamination prevention, and highly coordinated material flows. Unlike traditional manufacturing, where efficiency is often measured by volume, these facilities must protect the identity and integrity of each individual patient’s therapy throughout the production process.

In this model the facility serves as a critical safeguard for product quality and patient safety. Material flows, environmental controls, modular cleanroom design, utility systems, and digital tracking infrastructure become foundational components of a successful manufacturing operation.

Medical Devices Are Becoming Intelligent Platforms

Today’s medical devices are also evolving and extending innovation well beyond the drug molecule. No longer standalone products, medical devices are connected platforms that continuously collect, analyze, and respond to patient data. This convergence of hardware, software, sensors, and artificial intelligence is transforming how care is delivered and creating new manufacturing challenges in the process.

Some examples include ingestible sensors, wearable cardiac monitors, smart insulin pumps, implantable neuromodulation systems, nano-carriers, connected respiratory devices, and home diagnostic platforms.

Manufacturing these products requires convergence between pharmaceutical production, precision engineering, electronics assembly, and software validation. Few industries demand this level of multidisciplinary coordination, which is why the design and construction of the manufacturing environment play such a critical role.

The facilities built today must do more than house production equipment; they must enable collaboration across disciplines, support highly controlled manufacturing conditions, and provide a foundation for innovation as products and processes continue to evolve. In many cases, the facility itself becomes a strategic asset, helping manufacturers bring increasingly complex technologies to market faster and more reliably.

Rethinking Drug Delivery

The future of medicine may depend as much on how treatments are delivered as on the therapies themselves. New delivery methods are making treatments more convenient, enabling care outside traditional clinical settings, and improving the patient’s experience.

As treatments move closer to the home, expectations for product reliability, consistency, and ease of use continue to rise. In many cases, manufacturing environments must be designed to accommodate both pharmaceutical and device production requirements within a single operation.

For construction teams, the challenge is creating facilities capable of supporting this growing complexity while maintaining the flexibility needed to adapt as delivery technologies continue to advance. Products like ADC’s, long-acting injectable formulations, microneedle patch systems, targeted nanoparticle delivery, implantable reservoirs, inhaled biologics, connected autoinjectors, and on-body infusion devices are placing new demands on facility infrastructure, quality systems, and production workflows.

Why This Matters Beyond Healthcare

Regions capable of supporting advanced life sciences infrastructure stand to benefit from high-value job creation, increased private investment, stronger academic collaboration, greater domestic manufacturing resilience, and expanded innovation ecosystems.

The next generation of medicine factories will do more than produce therapies. They will anchor broader economic development, attract investment, and shape global competitiveness. As healthcare becomes more personal, connected, and precise, one reality remains unchanged: innovation at this level depends on environments that can support extreme technical, operational, and regulatory complexity.

At Evans, we see this shift firsthand in the work we deliver across healthcare, life sciences, and advanced manufacturing. Our role is to translate highly technical requirements into facilities that are constructible, controlled, and compliant, whether that involves complex cleanroom environments, regulated manufacturing spaces, or projects where precision, contamination control, and operational reliability are critical from day one.

As medicine becomes increasingly personalized, the role of construction continues to expand. The facilities being built today are not simply housing manufacturing processes, they are helping make the next generation of therapies possible.